Here are 1-2 brief analogies for SCYNEXIS (SCYX):

• SCYNEXIS is like Vertex Pharmaceuticals for fungal infections, focusing intensely on developing novel treatments to dominate a specific and challenging disease area.
• It's akin to an early Gilead Sciences for antifungal diseases, specializing in innovative therapies to combat severe and drug-resistant fungal infections, similar to how Gilead initially tackled HIV and Hepatitis C.

• enFungal™ Platform: A proprietary drug discovery platform focused on identifying and developing novel antifungal agents for serious fungal infections.
• SCY-247: A lead antifungal drug candidate derived from the enFungal™ platform, currently undergoing preclinical development for the treatment of invasive fungal infections.

SCYNEXIS (SCYX) is a biotechnology company focused on developing novel anti-infectives. Prior to March 2023, SCYNEXIS was directly commercializing its primary product, BREXAFEMME® (ibrexafungerp). However, the company has since significantly restructured its commercial strategy.

Effective March 27, 2023, SCYNEXIS entered into an exclusive license agreement with GSK (GlaxoSmithKline plc). Under this agreement, SCYNEXIS granted GSK the exclusive global rights to commercialize ibrexafungerp for all indications, including vulvovaginal candidiasis (VVC) and invasive fungal infections. SCYNEXIS also sold its U.S. commercial sales force and related infrastructure to GSK.

As a result of this transaction, SCYNEXIS's primary revenue streams are now derived from payments from GSK, including an upfront payment, potential future development and commercial milestone payments, and tiered royalties on future net sales of ibrexafungerp by GSK. Therefore, SCYNEXIS now primarily conducts business with other companies, with GSK being its major strategic partner and effectively its primary "customer" for the commercialization of its lead asset.

The major customer company for SCYNEXIS is:

• GSK (NYSE: GSK, LSE: GSK)

null

David Angulo, M.D. President and Chief Executive Officer

Dr. Angulo became President and Chief Executive Officer of SCYNEXIS in January 2023, having joined the company as Chief Medical Officer in 2015. He is an infectious disease specialist with over 20 years of experience in drug development. Prior to SCYNEXIS, he served as Vice President, Research and Development at Brickell Biotech, Inc. He also held various senior positions at Stiefel Laboratories, Inc. (a GSK company), including head of clinical and medical departments, and was responsible for anti-infective development programs at Schering-Plough Research Institute.

Ivor Macleod, MBA, CPA Chief Financial Officer

Mr. Macleod is a senior pharmaceutical executive with over 30 years of financial and operational experience in the life sciences industry. He joined SCYNEXIS from Athersys, Inc., where he served as Chief Financial Officer since January 2020. Before Athersys, he was the Chief Financial Officer and Chief Compliance Officer of Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., from 2015 to 2018.

Scott Sukenick Chief Legal Officer

Mr. Sukenick joined SCYNEXIS as General Counsel in November 2017. He has over a decade of experience addressing legal challenges for life sciences companies. His previous roles include working at Cooley LLP, where he focused on life sciences litigation and strategic intellectual property management, and Patterson Belknap Webb & Tyler LLP, where he primarily represented pharmaceutical and medical device companies in patent litigation.

Daniella Gigante Vice President, Human Resources and Information Technology

Ms. Gigante joined SCYNEXIS in October 2020, bringing over 22 years of human resources experience across various industries. Prior to SCYNEXIS, she spent eight years at Allergan as the Executive Director of Talent Acquisition. She also led Talent Acquisition teams at Pfizer and Schering-Plough.

Rossana Ferrara-Pontoriero, Ph.D. Vice President, Business Development and Alliance Management

Dr. Ferrara-Pontoriero joined SCYNEXIS in September 2016 and has held leadership roles in Commercial, Business Development, Strategic Planning, and Alliance Management. She possesses over 11 years of experience in the pharmaceutical and biotechnology industries, previously working in marketing at Celgene and Allergan, and in Global Commercial Assessments at Forest Laboratories.

The emergence of Oteseconazole (Vivjoa), an oral antifungal developed by Mycovia Pharmaceuticals (now part of Organon) and approved by the FDA in 2022 specifically for the treatment of recurrent vulvovaginal candidiasis (RVVC). Vivjoa directly competes with SCYNEXIS's primary product, BREXAFEMME (ibrexafungerp), which also targets RVVC and other forms of vulvovaginal candidiasis. The increased competition in this specific indication could impact the market share and adoption of BREXAFEMME, thereby affecting the future royalty stream SCYNEXIS receives from its license agreement with GSK.

SCYNEXIS (SCYX) focuses on developing and commercializing novel anti-infectives for challenging fungal infections. The company's main products and pipeline candidates include BREXAFEMME (ibrexafungerp tablets) for vulvovaginal candidiasis (VVC) and recurrent VVC, and ibrexafungerp (the active ingredient in BREXAFEMME) which is also being developed for invasive candidiasis and other serious invasive fungal infections, along with a next-generation antifungal candidate, SCY-247.

The addressable markets for SCYNEXIS's main products and pipeline are as follows:

• BREXAFEMME (ibrexafungerp) for Vulvovaginal Candidiasis (VVC) and Recurrent VVC (RVVC):
  • For BREXAFEMME specifically, the potential U.S. peak net sales for VVC are estimated to reach approximately $400 million by 2027.
  • The global candidiasis therapeutics market, which includes VVC treatments, was valued at $3.19 billion in 2024 and is projected to grow to $3.3 billion in 2025. It is expected to reach $3.83 billion by 2029.
• Ibrexafungerp for Invasive Candidiasis:
  • Invasive candidiasis is a life-threatening condition affecting approximately 750,000 people annually (global patient population).
  • The U.S. peak sales potential for ibrexafungerp in the invasive candidiasis market could reach between $300 million and $400 million per year.
• Overall Antifungal Drugs Market (relevant to ibrexafungerp and SCY-247):
  • The U.S. antifungal drugs market was an estimated $6.05 billion in 2024 and is projected to reach $7.20 billion by 2030.
  • Globally, the antifungal drugs market was valued at $16.24 billion in 2022 and is projected to reach approximately $22.8 billion by 2032.
• SCY-247 (for Invasive Fungal Infections, including Candida auris):
  • While a specific market size in USD for SCY-247 is not readily available, its market potential is underscored by the global rise in fungal infections and the urgent need to address invasive fungal infections, particularly drug-resistant strains like Candida auris.

Expected Drivers of Future Revenue Growth for SCYNEXIS (SCYX)

1. Relaunch and Commercialization of BREXAFEMME (Ibrexafungerp) by GSK: GSK remains committed to the relaunch of BREXAFEMME, a leading product for vulvovaginal candidiasis. SCYNEXIS is positioned to receive significant annual net sales milestones, potentially reaching up to $146 million, along with low-to-mid single-digit royalties from this collaboration.
2. Advancement of SCY-247 into Later-Stage Clinical Trials: SCYNEXIS's second-generation fungerp drug candidate, SCY-247, has demonstrated positive Phase 1 results. The company plans to initiate a Phase 1 study for an intravenous (IV) formulation and a Phase 2 oral study for the treatment of invasive candidiasis, with proof-of-concept data anticipated in 2026. Successful progression through these trials could unlock substantial future revenue.
3. Milestone Payments and Royalties from Existing and Future Partnerships: Beyond the direct sales of BREXAFEMME, SCYNEXIS is eligible for various milestone payments and royalties from its partnerships. This includes potential annual net sales milestones up to approximately $146 million and royalties from the BREXAFEMME relaunch. The broader ibrexafungerp deal with GSK also holds a total potential value of $448 million, encompassing development, regulatory approval, commercial, and sales milestone payments, in addition to royalties. A one-time payment of $24.8 million was received from GSK in Q4 2025, further bolstering financial stability.
4. Geographic Expansion of Ibrexafungerp: The approval of ibrexafungerp in China for acute vulvovaginal candidiasis treatment through a partnership with Hansoh represents a strategic expansion into new markets. This expansion is expected to trigger additional milestone payments and royalties, contributing to future revenue growth.

Share Issuance

• In April 2022, SCYNEXIS completed an underwritten public offering, generating gross proceeds of $45.0 million from the sale of common stock, pre-funded warrants, and warrants.
• The company undertook an $85 million equity financing in December 2020.
• The number of outstanding shares increased by 2.31% in one year, reaching 38,981,064 as of March 1, 2025.

Inbound Investments

• SCYNEXIS entered into an exclusive license agreement with GlaxoSmithKline (GSK) in March 2023, for which it received an upfront payment of $90.0 million in May 2023.
• The company received a $25.0 million development milestone payment in June 2023 and a $10.0 million milestone payment in July 2024 from GSK, both related to their license agreement.
• In October 2025, SCYNEXIS is set to receive one-time payments totaling $24.8 million from GSK as a resolution for the disagreement concerning the termination of the Phase 3 MARIO study.